Rare Mutations and Fusions Patient Gateway

About rare mutations and fusions in lung cancer

Currently, there are nine DNA-based alterations, or biomarkers, for which we have targeted therapies in NSCLC. Rare mutations and fusions include BRAF V600E, MET, NTRK, RET and ROS1.

Learn More

LATEST UPDATES

Find your Community

Whether you're living with lung cancer, or caring for someone with the disease, online groups and biomarker-specific communities can offer much-needed support.

Find your Community

Learn about
Clinical Trials

Participating in a research study may offer additional treatment options for those who are eligible.

Learn about Clinical Trials

Rare Mutations & Fusions Newsletter

Periodic emails with rare mutations & fusions news, events, and research advances

Rare Mutations & Fusions Newsletter

Sponsors

Abbvie       AstraZeneca       Bayer       Boehringer Ingelheim       Janssen